Peptide library
Your guide to this compound.
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. Plasma levels are below quantitation at labeled doses; a conventional systemic half-life cannot be calculated. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Eligibility and age limits depend on the labeled constipation indication.
Used for labeled constipation indications; it is not a systemic repair peptide.
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
Guanylate cyclase-C agonism increases intestinal fluid secretion.
Guanylate cyclase-C agonism increases intestinal fluid secretion. Age restrictions and severe diarrhea warnings matter. The full label is needed for patient selection.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
LINZESS: age under two years, or known/suspected mechanical gastrointestinal obstruction. The minimum age for IBS-C is seven; functional constipation labeling begins at age two. These indication-specific limits differ.
Named U.S. product only; label revision 20260521. Educational extraction, not complete clinical review.
Primary source · Linaclotide
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.